title: Induction immunosuppression in liver transplantation: a review.
abstract: Antibody therapy for induction is seldom used in liver transplantation in the United States, but continues to be used in approximately 10% of patients. The most commonly used antibody at the current time is basiliximab (Simulect, Novartis) and is used in adults with renal dysfunction at the time of liver transplantation with the intention of delaying introduction of calcineurin-inhibitors. In children, the same antibody is commonly used in order to reduce rates of acute rejection. Most patients, adult and pediatric, are treated with initially higher levels of tacrolimus rather than antibody induction.
authors: Emory University School of Medicine, Atlanta, GA 30322, USA.
authors: Alexandra P
authors: AP
authors: Turner
authors: Stuart J
authors: SJ
authors: Knechtle
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000077552:Basiliximab; D065095:Calcineurin Inhibitors; D006084:Graft Rejection / Q000517:prevention & control; D006526:Hepatitis C / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000009:adverse effects; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012008:Recurrence
chemical_list: D000911:Antibodies, Monoclonal; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab